Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U0KR
|
|||
| Former ID |
DCL001171
|
|||
| Drug Name |
CF102
|
|||
| Synonyms |
2-Cl-IB-Meca; 163042-96-4; Cl-IB-MECA; Namodenoson; C-Ibza-MU; CF-102; CI-IB-MECA; (2S,3S,4R,5R)-5-(2-Chloro-6-((3-iodobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxy-N-methyltetrahydrofuran-2-carboxamide; UNII-Z07JR07J6C; 2Cl-IB-MECA; 1-[2-CHLORO-6-[[(3-IODOPHENYL)METHYL]AMINO]-9H-PURIN-9-YL]-1-DEOXY-N-METHYL-BETA-D-RIBOFURANURONAMIDE; CHEMBL431733; Z07JR07J6C; CF102; 2-Chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 2 | [1] | |
| Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 1/2 | [2] | ||
| Company |
Can-Fite BioPharm
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H18ClIN6O4
|
|||
| Canonical SMILES |
CNC(=O)C1C(C(C(O1)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I)O)O
|
|||
| InChI |
1S/C18H18ClIN6O4/c1-21-16(29)13-11(27)12(28)17(30-13)26-7-23-10-14(24-18(19)25-15(10)26)22-6-8-3-2-4-9(20)5-8/h2-5,7,11-13,17,27-28H,6H2,1H3,(H,21,29)(H,22,24,25)/t11-,12+,13-,17+/m0/s1
|
|||
| InChIKey |
IPSYPUKKXMNCNQ-PFHKOEEOSA-N
|
|||
| CAS Number |
CAS 163042-96-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7978583, 10048454, 12015329, 14861420, 14910443, 24278354, 26752072, 36079220, 49689294, 56463287, 57353271, 77935341, 91703472, 103233890, 111639918, 124801294, 126671715, 128202599, 134339870, 135257010, 135650107, 135727665, 162249585, 171579234, 175437920, 176225179, 184596899, 196378206, 198987487, 215780668, 223393034, 223660941, 227406890, 241182133, 249853785, 250201872, 252077490, 252214276, 252433065
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adenosine A3 receptor (ADORA3) | Target Info | Agonist | [2] |
| Reactome | Adenosine P1 receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Nucleotide GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | 2011 Pipeline of Can-Fite BioPharm. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.